Published in Biochem Pharmacol on October 15, 2002
Neuronal characteristics of small-cell lung cancer. Br J Cancer (2005) 1.05
How does cancer cell metabolism affect tumor migration and invasion? Cell Adh Migr (2013) 1.04
Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem (2012) 1.02
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01
Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis (2009) 1.00
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res (2014) 0.92
Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One (2012) 0.87
Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatol Int (2005) 0.85
Immunomodulatory effects of domoic acid differ between in vivo and in vitro exposure in mice. Mar Drugs (2008) 0.84
N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol (2005) 0.84
Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol (2015) 0.83
Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget (2015) 0.83
Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation. PLoS Pathog (2014) 0.79
A novel analysis strategy for integrating methylation and expression data reveals core pathways for thyroid cancer aetiology. BMC Genomics (2015) 0.79
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. J Neurosurg (2014) 0.75
Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway. Oncol Lett (2017) 0.75
Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A (2002) 4.18
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci (2008) 4.04
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol (2002) 3.30
Anesthesia-induced developmental neuroapoptosis. Does it happen in humans? Anesthesiology (2004) 3.22
Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum (2010) 2.50
Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol (2008) 2.46
Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci (2003) 2.01
Ethanol-induced apoptotic neurodegeneration in the developing C57BL/6 mouse brain. Brain Res Dev Brain Res (2002) 1.89
Do pediatric drugs cause developing neurons to commit suicide? Trends Pharmacol Sci (2004) 1.67
Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol (2005) 1.51
Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol (2004) 1.49
Suppression of the intrinsic apoptosis pathway by synaptic activity. J Neurosci (2010) 1.40
Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol (2010) 1.33
Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol (2009) 1.31
NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A (2005) 1.30
Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis (2004) 1.30
Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol (2007) 1.26
Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis (2004) 1.23
Oxygen causes cell death in the developing brain. Neurobiol Dis (2004) 1.18
Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol (2004) 1.13
Neurodegeneration in newborn rats following propofol and sevoflurane anesthesia. Neurotox Res (2009) 1.11
The enigma of fetal alcohol neurotoxicity. Ann Med (2002) 1.08
Brief alteration of NMDA or GABAA receptor-mediated neurotransmission has long term effects on the developing cerebral cortex. Mol Cell Proteomics (2008) 1.07
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A (2005) 1.06
Antiepileptic drugs and brain development. Epilepsy Res (2009) 1.04
The role of matrix metalloproteinases in infant traumatic brain injury. Neurobiol Dis (2006) 1.03
Multiple sclerosis and glutamate. Ann N Y Acad Sci (2003) 1.03
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther (2010) 0.98
Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res (2011) 0.97
Pathways leading to apoptotic neurodegeneration following trauma to the developing rat brain. Neurobiol Dis (2002) 0.95
Caspase-1-processed interleukins in hyperoxia-induced cell death in the developing brain. Ann Neurol (2005) 0.93
Glutamate and its receptors in cancer. J Neural Transm (Vienna) (2014) 0.92
Protection with estradiol in developmental models of apoptotic neurodegeneration. Ann Neurol (2005) 0.91
Neuropathological sequelae of developmental exposure to antiepileptic and anesthetic drugs. Front Neurol (2012) 0.90
Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther (2008) 0.90
Toxicity of tungsten carbide and cobalt-doped tungsten carbide nanoparticles in mammalian cells in vitro. Environ Health Perspect (2008) 0.87
Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity. Ann Neurol (2008) 0.86
Glutamate and GABA receptor dysfunction in the fetal alcohol syndrome. Neurotox Res (2002) 0.85
Apoptotic neurodegeneration in the context of traumatic injury to the developing brain. Exp Toxicol Pathol (2004) 0.84
Mechanisms of disease: motoneuron disease aggravated by transgenic expression of a functionally modified AMPA receptor subunit. Ann N Y Acad Sci (2005) 0.84
Glutamate receptors in laryngeal cancer cells. Anticancer Res (2011) 0.84
Neuropathological and biochemical features of traumatic injury in the developing brain. Neurotox Res (2003) 0.84
Novel soft alginate hydrogel strongly supports neurite growth and protects neurons against oxidative stress. Tissue Eng Part A (2011) 0.83
AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. Cancer Biol Ther (2007) 0.83
Matrix metalloproteinase 9 regulates cell death following pilocarpine-induced seizures in the developing brain. Neurobiol Dis (2012) 0.82
Impact of chemotherapy for childhood leukemia on brain morphology and function. PLoS One (2013) 0.82
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. Am J Physiol Endocrinol Metab (2011) 0.81
Activation of caspase-1 dependent interleukins in developmental brain trauma. Neurobiol Dis (2006) 0.81
Swelling and mechanical properties of alginate hydrogels with respect to promotion of neural growth. Tissue Eng Part C Methods (2013) 0.80
Glutamate antagonists are neurotoxins for the developing brain. Neurotox Res (2007) 0.78
Developing BACE-1 inhibitors for FXS. Front Cell Neurosci (2013) 0.78
Ehlers-Danlos syndrome type VI with cystic malformations of the meninges in a 7-year-old girl. Eur J Pediatr (2004) 0.77
Matrix metalloproteinases 2 and 9 fail to influence drug-induced neuroapoptosis in developing rat brain. Neurotox Res (2010) 0.76
Subacute proteome changes following traumatic injury of the developing brain: Implications for a dysregulation of neuronal migration and neurite arborization. Proteomics Clin Appl (2007) 0.76
17 beta-estradiol modulates GABAergic synaptic transmission and tonic currents during development in vitro. Neuropharmacology (2007) 0.75
Tolerance to and Dependence on Alprazolam are Due to Changes in GABAa Receptor Function and Are Independent of Exposure to Experimental Set-up. Restor Neurol Neurosci (1998) 0.75